



## Phase I Dog Trial with New Monepantel Tablets Commences

- Phase I trial program commences on time aiming to validate tablet performance
- First data expected mid-March
- Trial is precursor for Phase II dog cancer trial

**20 February 2019 – Perth, Australia:** PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has commenced its Phase I trial program in canines using its reformulated monepantel tablets.

These tablets were manufactured according to the scaled production method successfully developed and announced on 7 February 2019 along with the Phase I trial design. The first data set describing tablet performance is expected mid-March 2019.

PharmAust's Chief Scientific Officer Dr Richard Mollard stated, "PharmAust is pleased that the Phase I trial in dogs has commenced on time. The first and current Phase I component aims to validate the performance of the scaled tablet in different dietary settings that dogs may encounter at home with their owners."

"PharmAust will then commence the second component of the Phase I trial, aiming to confirm the safety previously demonstrated during treatment with monepantel. This study will determine the dose and frequency of administration required for the predicted anti-cancer activity. Such performance characteristics of the scaled tablet are required before the longer term dosing and evaluation of the tablets in the subsequent Phase II studies can be undertaken."

### Enquiries:

**Dr Roger Aston**  
Executive Chairman and CEO  
Tel: 0402 762 204  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

**Dr Richard Mollard**  
Chief Scientific Officer  
Tel: 0418 367 855  
[rmollard@pharmaust.com](mailto:rmollard@pharmaust.com)

### About PharmAust (PAA):

PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, EpiChem, a highly successful contract medicinal chemistry company which generated ~Aus\$3.02m in revenues in the 2018 FY.